Your account is not claimed yet. You can sign up with ORCID to claim your account.

Miles Patrick Sparrow (M P Sparrow, M Sparrow, Miles P Sparrow)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Venues

Alimentary pharmacology & therapeutics

Internal medicine journal

Digestive diseases and sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Kathryn Gazelakis, Isabel Chu, Catherine Martin, Miles Patrick Sparrow
Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal medicine journal (2023)
Kathryn Gazelakis, Isabel Chu, Catherine Martin, Miles Patrick Sparrow
Infections In Inflammatory Bowel Disease Patients on Immunomodulator and Biologic Therapy are Not Associated With High Serum Drug Levels. Internal medicine journal (2023)
Karla Cameron, Miles Patrick Sparrow
Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Alimentary pharmacology & therapeutics 55 (8) (2022)
Alexander Keith Bain Turbayne, Miles Patrick Sparrow
Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo. Digestive diseases and sciences 67 (12) (2022)
Emma K Flanagan, Emily K Wright, Winita Hardikar, Miles Patrick Sparrow, William R Connell, Michael A Kamm, Peter De Cruz, Steven J Brown, Alexander Thompson, Anthea Greenway, Ian Westley, Murray L Barclay, Alyson L Ross, Katerina V Kiburg, Sally J Bell, null null
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary pharmacology & therapeutics 53 (7) (2021)
Dorit V Ankersen, Savannah Noack, Pia Munkholm, Miles Patrick Sparrow
E-Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of need. Internal medicine journal 51 (8) (2021)
Robert Little, Miles Patrick Sparrow
Editorial: anti-drug antibodies and the benefit of assay validation. Alimentary pharmacology & therapeutics 53 (1) (2021)
David J Gibson, Mark G Ward, Clarissa Rentsch, Antony B Friedman, Kirstin M Taylor, Miles Patrick Sparrow, Peter R Gibson
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (6) (2020)
Abhinav Vasudevan, Nina Parthasarathy, Danny Con, Steven Nicolaides, Ross Apostolov, Ayushi Chauhan, Maria Bishara, Raphael P Luber, Neetima Joshi, Anna Wan, James A Rickard, Tony Long, Declan Connoley, Miles Patrick Sparrow, Peter R Gibson, Daniel R Van Langenberg
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (7) (2020)
Anke L H Nguyen, Miles Patrick Sparrow
Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Digestive diseases and sciences 66 (10) (2020)
Emma K Flanagan, Peter R Gibson, Emily K Wright, Gregory T Moore, Miles Patrick Sparrow, William Connell, Michael A Kamm, Jakob Begun, Britt Christensen, Peter De Cruz, Edward Shelton, Damian Dowling, Jane M Andrews, Steven J Brown, Olga D Niewiadomski, Mark G Ward, Ourania Rosella, Gennaro Rosella, Katerina V Kiburg, Alyson L Ross, Sally J Bell, null null
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary pharmacology & therapeutics 52 (10) (2020)
Zaid S Ardalan, Chu Kion Yao, Miles Patrick Sparrow, Peter R Gibson
Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis. Alimentary pharmacology & therapeutics 52 (8) (2020)
Antony B Friedman, Miles Patrick Sparrow
Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 48 (1) (2019)
Miles Patrick Sparrow
Editorial: clinical trials in IBD-how much of a difference is enough? Alimentary pharmacology & therapeutics 47 (7) (2019)
Antony B Friedman, S J Brown, P Bampton, Murray L Barclay, A Chung, F A Macrae, J McKenzie, J Reynolds, P R Gibson, Stephen Hanauer, Miles Patrick Sparrow
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Alimentary pharmacology & therapeutics 47 (8) (2018)
Mark G Ward, P R Gibson, Miles Patrick Sparrow
Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply. Alimentary pharmacology & therapeutics 45 (11) (2017)
B Christensen, Miles Patrick Sparrow
Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog? Alimentary pharmacology & therapeutics 45 (9) (2017)
Nikola Mitrev, N Vande Casteele, Cynthia H-T Seow, J M Andrews, S J Connor, G T Moore, M Barclay, J Begun, R Bryant, Webber Pak Wo Chan, C Corte, S Ghaly, D A Lemberg, V Kariyawasam, P Lewindon, J Martin, R Mountifield, G Radford-Smith, P Slobodian, Miles Patrick Sparrow, C Toong, D van Langenberg, Mark G Ward, Rupert W L Leong, null null
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary pharmacology & therapeutics 46 (11-12) (2017)

Miles Patrick Sparrow.css-eqlu8i{font-size:small;padding-left:4px;} (M P Sparrow, M Sparrow, Miles P Sparrow)

Publication Activity (10 Years)

Top Topics

Top Venues

Miles Patrick Sparrow (M P Sparrow, M Sparrow, Miles P Sparrow)